Surufatinib
Phase 3Completed 0 watching 0 views this weekπ Rising
72
Development Stage
β
Pre-clinicalβ
Phase 1β
Phase 24
Phase 35
ApprovedIndication / Disease
Neuroendocrine Tumors
Conditions
Neuroendocrine Tumors
Trial Timeline
Dec 7, 2015 β Jul 7, 2022
NCT ID
NCT02589821About Surufatinib
Surufatinib is a phase 3 stage product being developed by HUTCHMED for Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02589821. Target conditions include Neuroendocrine Tumors.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04814732 | Pre-clinical | Completed |
| NCT05077384 | Phase 1/2 | Completed |
| NCT04579679 | Phase 2 | Terminated |
| NCT04372394 | Phase 1 | Completed |
| NCT02966821 | Phase 2 | Completed |
| NCT02614495 | Phase 2 | Completed |
| NCT02588170 | Phase 3 | Completed |
| NCT02589821 | Phase 3 | Completed |
| NCT02549937 | Phase 1/2 | Completed |
Competing Products
20 competing products in Neuroendocrine Tumors
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| [203Pb]VMT-Ξ±-NET + [212Pb]VMT-Ξ±-NET | Perspective Therapeutics | Phase 1/2 | 33 |
| [203Pb]VMT-Ξ±-NET | Perspective Therapeutics | Phase 1 | 25 |
| [212Pb] VMT-Ξ±-NET | Perspective Therapeutics | Phase 1 | 25 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| Abemaciclib | Eli Lilly | Phase 2 | 52 |
| Lutetium (177Lu) Oxodotreotide InjectionοΌlong-acting Octreotide + long-acting Octreotide. | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Famitinib | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| 68Ga-DOTATOC | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Olaparib | AstraZeneca | Phase 2 | 52 |
| Avelumab | Merck | Phase 1/2 | 41 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Pembrolizumab Injection | Merck | Phase 2 | 52 |
| Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab | Merck | Phase 1 | 33 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Lenvatinib | Merck | Phase 2 | 52 |
| Avelumab | Merck | Phase 2 | 52 |
| Pembrolizumab + Irinotecan + Paclitaxel | Merck | Phase 2 | 52 |
| MK-0646 | Merck | Phase 2 | 52 |